NCT06981390
Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Eligibility criteria shortened, about 5 words
- Site details revised
Notable Primary completion date: Feb 20, 2026 to Feb 20, 2027v3 Show 4 more changesShow less
- Start date: Feb 1, 2025 to May 1, 2026
- Trial status: Recruiting to Not Yet Recruiting
- Study completion date: Mar 20, 2026 to Mar 20, 2027
- Site details revised
Notable Phase: Phase 1 to Not applicablev2 Show 5 more changesShow less
- Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Primary completion date: Oct 20, 2026 to Feb 20, 2026
- Study completion date: Dec 20, 2026 to Mar 20, 2026
- Start date changed from estimate of Jun 1, 2025 to Feb 1, 2025
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Saphenous Vein Graft (SVG) Patency at 12 Months
Timeframe: 12 months post-CABG
Secondary (3)
Bleeding Events
MACCE episodes
All-Cause Mortality
Arms and interventions
3-Month DAPT GroupActive comparator
Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, followed by aspirin monotherapy
6-Month DAPT GroupActive comparator
Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 6 months, followed by aspirin monotherapy
12-Month DAPT GroupExperimental
Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 12 months, followed by aspirin monotherapy
Drugs: Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)
Sites
1 site in 1 country
- the Second Hospital of Jilin UniversityChangchun, Jilin, China